Table A3.

CTNNB1 Quartiles by Patient and Disease Characteristics

Characteristic	CTNNB1 Quartiles								All
	Q1		Q2		Q3		Q4
	No.	%	No.	%	No.	%	No.	%	No.	%
Treatment
Standard	6	14.6	8	19.5	9	22.5	9	21.4	32	19.5
Hypofractionation	7	17.1	14	34.1	14	35.0	14	33.3	49	29.9
Split-course accelerated fractionation	21	51.2	14	34.1	10	25.0	9	21.4	54	32.9
Accelerated fractionation with concomitant boost	7	17.1	5	12.2	7	17.5	10	23.8	29	17.7
Sex
Male	32	78.0	34	82.9	32	80.0	34	81.0	132	80.5
Female	9	22.0	7	17.1	8	20.0	8	19.0	32	19.5
KPS
60	3	7.3	3	7.3	1	2.5	2	4.8	9	5.5
70	7	17.1	6	14.6	7	17.5	7	16.7	27	16.5
80	11	26.8	12	29.3	15	37.5	5	11.9	43	26.2
90	15	36.6	17	41.5	12	30.0	24	57.1	68	41.5
100	5	12.2	3	7.3	5	12.5	4	9.5	17	10.4
Age, years
≤ 55	9	22.0	20	48.8	16	40.0	11	26.2	56	34.1
56-65	18	43.9	11	26.8	15	37.5	16	38.1	60	36.6
≥ 66	14	34.1	10	24.4	9	22.5	15	35.7	48	29.3
Primary site
Oral cavity	4	9.8	4	9.8	4	10.0	3	7.1	15	9.1
Oropharynx	26	63.4	27	65.9	20	50.0	27	64.3	100	61.0
Hypopharynx	6	14.6	5	12.2	2	5.0	5	11.9	18	11.0
Larynx	5	12.2	5	12.2	14	35.0	7	16.7	31	18.9
T stage
T1	2	4.9	1	2.4	2	5.0	1	2.4	6	3.7
T2	11	26.8	5	12.2	5	12.5	16	38.1	37	22.6
T3	21	51.2	25	61.0	17	42.5	13	31.0	76	46.3
T4	7	17.1	10	24.4	16	40.0	12	28.6	45	27.4
N stage
N0	11	26.8	10	24.4	10	25.0	9	21.4	40	24.4
N1	10	24.4	10	24.4	3	7.5	10	23.8	33	20.1
N2a	1	2.4	3	7.3	3	7.5	4	9.5	11	6.7
N2b	11	26.8	9	22.0	7	17.5	6	14.3	33	20.1
N2c	7	17.1	5	12.2	11	27.5	8	19.0	31	18.9
N3	1	2.4	4	9.8	6	15.0	5	11.9	16	9.8

Abbreviations: CTNNB1, beta-catenin; Q, quartile; KPS, Karnofsky performance score.